Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalised Azacitidine Combination Therapy in Solid Tumours
NCT05381038Phase 2Recruiting
- Sponsor
- National University Hospital
- Start
- Feb 2023
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine in solid tumor, breast cancer and gastric cancer (GC), sponsored by National University Hospital. Primary endpoints: Percentage of participants with successful application of QPOP drug selection up to 18 months and Percentage of participants in whom the investigators successfully apply CURATE.AI profile up to 18 months. Started Feb 2023; status: recruiting.
02
Drugs
azacitidine
03
Conditions
solid tumorbreast cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT05381038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05381038.